10,000 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Acquired by Clarus Wealth Advisors

Clarus Wealth Advisors purchased a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $133,000.

A number of other hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Vanda Pharmaceuticals by 5.2% during the 2nd quarter. BlackRock Inc. now owns 8,987,677 shares of the biopharmaceutical company’s stock worth $126,636,000 after buying an additional 447,529 shares during the period. Renaissance Technologies LLC raised its stake in Vanda Pharmaceuticals by 9.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,798,050 shares of the biopharmaceutical company’s stock worth $39,425,000 after buying an additional 233,300 shares during the period. Macquarie Group Ltd. raised its stake in Vanda Pharmaceuticals by 10.5% during the 2nd quarter. Macquarie Group Ltd. now owns 2,604,692 shares of the biopharmaceutical company’s stock worth $36,700,000 after buying an additional 247,850 shares during the period. Invesco Ltd. raised its stake in Vanda Pharmaceuticals by 1.6% during the 2nd quarter. Invesco Ltd. now owns 1,521,183 shares of the biopharmaceutical company’s stock worth $21,434,000 after buying an additional 24,525 shares during the period. Finally, Stonepine Capital Management LLC raised its stake in Vanda Pharmaceuticals by 6.5% during the 2nd quarter. Stonepine Capital Management LLC now owns 1,341,943 shares of the biopharmaceutical company’s stock worth $18,908,000 after buying an additional 81,655 shares during the period.

Shares of VNDA opened at $12.71 on Friday. The stock has a 50 day moving average price of $13.65 and a two-hundred day moving average price of $14.95. The firm has a market capitalization of $677.11 million, a P/E ratio of 26.48 and a beta of 0.32. Vanda Pharmaceuticals Inc. has a 52 week low of $11.83 and a 52 week high of $33.44.



Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.24. The firm had revenue of $59.06 million during the quarter, compared to analyst estimates of $54.19 million. Vanda Pharmaceuticals had a return on equity of 10.23% and a net margin of 13.61%. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.15 EPS. On average, analysts expect that Vanda Pharmaceuticals Inc. will post 0.32 earnings per share for the current year.

A number of research firms recently weighed in on VNDA. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research note on Saturday, October 5th. Citigroup raised Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Thursday, August 1st. Stifel Nicolaus reaffirmed a “hold” rating and set a $17.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, July 31st. Finally, ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $26.71.

In other Vanda Pharmaceuticals news, Director Richard W. Dugan sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.85, for a total transaction of $222,750.00. Following the completion of the sale, the director now directly owns 50,770 shares of the company’s stock, valued at approximately $753,934.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Timothy Williams sold 2,575 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $14.69, for a total value of $37,826.75. Following the sale, the senior vice president now directly owns 57,425 shares of the company’s stock, valued at $843,573.25. The disclosure for this sale can be found here. Insiders own 8.20% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: What are some reasons analysts would give stocks a buy rating?

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.